Our study demonstrates that HSD3B1 genotypes distinctly impact tumor transcriptional profiles, genomic alterations, and the expression of immune and non-immune pathways across BC and EC subtypes, in both pre- and postmenopausal tumors. This evidence concerns the gene HSD3B1 and neoplasm.